Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Perkovic, Vlado; Jardine, Meg; Neal, Bruce; Bompoint, Séverine; J.L. Heerspink, Hiddo; M. Charytan, David; Edwards, Robert; Agarwal, Rajiv; L. Bakris, George; Bull, Scott; P. Cannon, Christopher; Capuano, George; Chu, Pei-Ling; de Zeeuw, Dick; Greene, Tom; Levin, Adeera; A. Pollock, Carol; C. Wheeler, David; Yavin, Yshai; Zhang, Hong; Zinman, Bernard; Meininger, Gary; M. Brenner, Barry; W. Mahaffey, Kenneth

doi:10.1056/nejmoa1811744

Public

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Published in New England Journal of Medicine • Apr 14, 2019

Authors:

Vlado Perkovic

Meg Jardine

Bruce Neal

Abstract

BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes...

Subject

Canagliflozin

Medicine

Type 2 diabetes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!